For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.
Multiple Myeloma/Advanced Solid Tumours
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
ZOMETA is approved for use in the following countries: Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Curacao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Moldova, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Republic Srpska, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Syria, Taiwan, Thailand, The Netherlands, Trinidad and Tobago, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Venezuela.
Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.
ZOMETA International Website
This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
ZOMETA has demonstrated tolerability across multiple myeloma and advanced solid tumours1
A well-established profile in patients with advanced cancers and multiple myeloma1
ZOMETA has been prescribed to more than 4 million patients worldwide2
The acute-phase reaction associated with ZOMETA administration is usually transient, lessens with subsequent infusions, and is consistent with symptoms of immune system activation1,3,4
ZOMETA has been generally well tolerated in combination with endocrine therapy and chemotherapy regimens in multiple clinical trials5-8
In multiple myeloma and advanced solid tumours, ZOMETA offers a well-known renal safety profile1
*Defined as >3x upper limit of normal.
The ZOMETA dose must be adjusted for patients with mild to moderate renal impairment. ZOMETA is not recommended for patients with severe renal impairment (CrCl <30 mL/min) prior to initiation of therapy.1
References: 1. ZOMETA Summary of Product Characteristics. Novartis Pharma AG. 2. Data on file. Novartis Pharmaceuticals Corporation. 3. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005;10:52-62. 4. Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. Ann Oncol. 2007;18:201-202. 5. Rosen LS, Gordon D, Kaminski M, et al; Zoledronic Acid Breast Cancer and Multiple Myeloma Study Group. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744. 6. Rosen LS, Gordon D, Tchekmedyian NS, et al; Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 7. Saad F, Gleason DM, Murray R, et al; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 8. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 9. ZOMETA US Prescribing Information. Novartis Pharmaceuticals Corporation.
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Italiano
Français
Español
Deutsch
English
